AP639A - Polymorphs of the pro drug 6-n-(L-Ala-L-Ala)-trovafloxacin. - Google Patents

Polymorphs of the pro drug 6-n-(L-Ala-L-Ala)-trovafloxacin. Download PDF

Info

Publication number
AP639A
AP639A APAP/P/1996/000854A AP9600854A AP639A AP 639 A AP639 A AP 639A AP 9600854 A AP9600854 A AP 9600854A AP 639 A AP639 A AP 639A
Authority
AP
ARIPO
Prior art keywords
pll
polymorph
treating
pii
compound
Prior art date
Application number
APAP/P/1996/000854A
Other languages
English (en)
Other versions
AP9600854A0 (en
Inventor
Timothy Norris
James John Mcgarry
Douglas John Meldrum Allen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP9600854A0 publication Critical patent/AP9600854A0/xx
Application granted granted Critical
Publication of AP639A publication Critical patent/AP639A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
APAP/P/1996/000854A 1995-08-29 1996-08-29 Polymorphs of the pro drug 6-n-(L-Ala-L-Ala)-trovafloxacin. AP639A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US510995P 1995-08-29 1995-08-29

Publications (2)

Publication Number Publication Date
AP9600854A0 AP9600854A0 (en) 1996-10-31
AP639A true AP639A (en) 1998-04-14

Family

ID=21714229

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1996/000854A AP639A (en) 1995-08-29 1996-08-29 Polymorphs of the pro drug 6-n-(L-Ala-L-Ala)-trovafloxacin.

Country Status (35)

Country Link
US (1) US6080756A (uk)
EP (1) EP0847400B1 (uk)
JP (1) JPH11509188A (uk)
KR (1) KR100274736B1 (uk)
CN (1) CN1193977A (uk)
AP (1) AP639A (uk)
AR (1) AR004507A1 (uk)
AT (1) ATE208790T1 (uk)
AU (1) AU696414B2 (uk)
BR (1) BR9610283A (uk)
CA (1) CA2230303C (uk)
CO (1) CO4480740A1 (uk)
CZ (1) CZ291524B6 (uk)
DE (1) DE69617027T2 (uk)
DK (1) DK0847400T3 (uk)
DZ (1) DZ2088A1 (uk)
ES (1) ES2164892T3 (uk)
GT (1) GT199600061A (uk)
HR (1) HRP960396A2 (uk)
HU (1) HUP9900226A3 (uk)
IL (1) IL122652A (uk)
MA (1) MA23965A1 (uk)
NO (1) NO309039B1 (uk)
NZ (1) NZ310542A (uk)
OA (1) OA10670A (uk)
PL (1) PL185709B1 (uk)
PT (1) PT847400E (uk)
RU (1) RU2151152C1 (uk)
SK (1) SK283354B6 (uk)
TN (1) TNSN96110A1 (uk)
TR (1) TR199800340T1 (uk)
UA (1) UA48982C2 (uk)
WO (1) WO1997008191A1 (uk)
YU (1) YU48296A (uk)
ZA (1) ZA967281B (uk)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1998000106A (es) * 1997-08-01 1999-01-08 Pfizer Prod Inc Composiciones parenterales de alatroflaxacino
US6239141B1 (en) * 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
CN105510497A (zh) * 2015-11-30 2016-04-20 精晶药业股份有限公司 L-丙氨酰-l-丙氨酸的定量检测方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164402A (en) * 1989-08-16 1992-11-17 Pfizer Inc Azabicyclo quinolone and naphthyridinone carboxylic acids

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164402A (en) * 1989-08-16 1992-11-17 Pfizer Inc Azabicyclo quinolone and naphthyridinone carboxylic acids

Also Published As

Publication number Publication date
NO309039B1 (no) 2000-12-04
CZ291524B6 (cs) 2003-03-12
AP9600854A0 (en) 1996-10-31
CA2230303A1 (en) 1997-03-06
SK283354B6 (sk) 2003-06-03
ES2164892T3 (es) 2002-03-01
EP0847400A1 (en) 1998-06-17
PL325203A1 (en) 1998-07-06
HUP9900226A2 (hu) 1999-05-28
YU48296A (sh) 1998-12-23
PT847400E (pt) 2002-03-28
IL122652A0 (en) 1996-08-16
EP0847400B1 (en) 2001-11-14
DK0847400T3 (da) 2002-03-25
PL185709B1 (pl) 2003-07-31
SK23798A3 (en) 1999-05-07
MA23965A1 (fr) 1997-04-01
KR19990044231A (ko) 1999-06-25
CO4480740A1 (es) 1997-07-09
MX9801665A (es) 1998-08-30
WO1997008191A1 (en) 1997-03-06
HRP960396A2 (en) 1998-04-30
AU696414B2 (en) 1998-09-10
DE69617027T2 (de) 2002-03-21
UA48982C2 (uk) 2002-09-16
NO980863L (no) 1998-02-27
ZA967281B (en) 1998-03-02
HUP9900226A3 (en) 1999-11-29
KR100274736B1 (ko) 2000-12-15
CA2230303C (en) 2001-07-24
US6080756A (en) 2000-06-27
DE69617027D1 (de) 2001-12-20
ATE208790T1 (de) 2001-11-15
JPH11509188A (ja) 1999-08-17
GT199600061A (es) 1998-01-31
TR199800340T1 (xx) 1998-06-22
BR9610283A (pt) 1999-03-16
NZ310542A (en) 1999-09-29
AU6135196A (en) 1997-03-19
AR004507A1 (es) 1998-12-16
OA10670A (en) 2000-11-06
NO980863D0 (no) 1998-02-27
DZ2088A1 (fr) 2002-07-22
IL122652A (en) 2000-01-31
CZ55298A3 (cs) 1999-02-17
CN1193977A (zh) 1998-09-23
TNSN96110A1 (fr) 2005-03-15
RU2151152C1 (ru) 2000-06-20

Similar Documents

Publication Publication Date Title
KR100668400B1 (ko) 테트라히드로피리도에테르
JP3145715B2 (ja) 無水７−（［１α，５α，６α］−６−アミノ−３−アザビシクロ［３．１．０］ヘキサ−３−イル）−６−フルオロ−１−（２，４−ジフルオロフェニル）−１，４−ジヒドロ−４−オキソ−１，８−ナフチリディン−３−カルボン酸メタンスルホン酸塩の新規な結晶形態
BG104105A (bg) Алатрофлоксацинови парентерални състави
AP639A (en) Polymorphs of the pro drug 6-n-(L-Ala-L-Ala)-trovafloxacin.
FI70412C (fi) Foerfarande foer framstaellning av ergolinderivat
AU704115B2 (en) Zwitterionic forms of trovafloxacin
US6476020B1 (en) Imidazo-benzazepine compounds, their compositions and uses
US6066647A (en) Zwitterionic forms of trovafloxacin
KR20140048433A (ko) 신규한 스트렙토클로린 유도체 및 이를 유효성분으로 하는 암 질환의 예방 및 치료용 약학조성물
CA2247929A1 (en) Processes for the preparation of erythromycin derivatives
WO2002018344A1 (fr) Nouveaux derives esteriques ou amidiques
JPS59199693A (ja) インドリルグリシルセフアロスポリン誘導体
JP3068175B2 (ja) イソチアゾロ〔５，４―ｂ〕ピリジン誘導体
CS236782B2 (en) Processing of 5 s-(2r-butyl)peptidergotalkaloid
MXPA98001665A (en) Polymorphoses of profarmaco of 6-n- (l-ala-l-ala) -trovafloxacin, procedure for its preparation and use of mis
AP788A (en) Novel crystal form of anhydrous 7-(1a, 5a, 6a)-6-Amino-3-Azabicyclo(3.1.0) hex-3-YI)-6-Fluoro-1-(2,4- Difluorophenyl)-1,4-Dihydro-4-Oxo-1, 8-Naphthyridine-3-Carboxylic Acid, Methanesulfonic acid salt.
CS138391A3 (en) Pyrrolo (2,3-b/indole ketones and their analogues, method of their preparation and their application as drugs
JP2001527076A (ja) 海綿動物から単離されるアスマリンａ及びｂを含む細胞毒性アルカロイド誘導体